Autolus Therapeutics

AUTLNasdaq United Kingdom Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$561.589 M

$2.11 +5.50%

Close of 7 Aug 2026

Revenue

$10.1M

#3166 by revenue

Earnings

-$287.5M

Loss-making

Shares outstanding

266,143,286

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#61Zura BioZURA$566.7M
#624D Molecular TherapeuticsFDMT$562.0M
#63Autolus TherapeuticsAUTL$561.6M
#64Prime MedicinePRME$556.3M
#65RegenxbioRGNX$554.2M

Where these numbers come from

Share counts and financials for Autolus Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.